ATM and B-cell chronic lymphocytic leukemia: Our findings can be also of interest regarding use of ATR inhibitors, which are promising treatment option for CLL patients with ATM/TP53 defects [20], corroborating that use of these molecules has to be strictly kept for patients with a high proportion of TP53/ATM-defective subclones.